Chemotherapy-induced nausea and vomiting in daily clinical practice: A community hospital-based study

Supportive Care in Cancer

Volumn 20, Issue 1, 2012, Pages 107-117

  Hilarius, Doranne L ^a   Kloeg, Paul H ^b   Van Der Wall, Elsken ^c   Van Den Heuvel, Joris J G ^d   Gundy, Chad M ^e   Aaronson, Neil K ^e  

^a RED CROSS HOSPITAL   (Netherlands)

^b Location Alkmaar   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^e NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Antiemetics; Chemotherapy induced nausea and vomiting; Symptom management

Indexed keywords

ANTHRACYCLINE; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; APREPITANT; CARBOPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; IFOSFAMIDE; IRINOTECAN; LORAZEPAM; METHOTREXATE; METOCLOPRAMIDE; PROCHLORPERAZINE; SEROTONIN 3 ANTAGONIST;

ACUTE DISEASE; ADULT; ADVERSE OUTCOME; AGED; ALCOHOL CONSUMPTION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; COMMUNITY HOSPITAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; SEX DIFFERENCE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIEMETICS; ANTINEOPLASTIC AGENTS; FEMALE; HOSPITALS, GENERAL; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; NETHERLANDS; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; RISK FACTORS; SEX FACTORS; TIME FACTORS; VOMITING; YOUNG ADULT;

EID: 83555173626     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-010-1073-9     Document Type: Article

References (23)

1. Antiemesis. NCCN practice guidelines in oncology-v.1.2007. www.nccn.org
2. Hesketh PJ, Gandara DR (1991) Serotonin antagonists: a new class of antiemetic agents. J Natl Cancer Inst 83:613-620
3. Hesketh PJ, Grunberg SM, Gralla RJ et al (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J Clin Oncol 21:4112-4119 (Pubitemid 46606178)
4. De Wit R, Herrstedt J, Rapoport B et al (2004) The oral NK(1) antagonist aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy. Eur J Cancer 40:403-410
5. Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J (2006) Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24:4472-4478 (Pubitemid 46630986)
6. D'Acquisto R, Tyson LB, Gralla RJ (1986) The influence of a chronic high alcohol intake on chemotherapy-induced nausea and vomiting. Proc Am Soc Clin Oncol 5:257
7. Hesketh PJ, Plagge P, Bryson JC (1992) Single-dose ondanse-tron for prevention of acute cisplatin-induced emesis: analysis of efficacy and prognostic factors. In: Bianchi AL, Grelot L, Miller Ad (eds) Mechanisms and control of emesis. Libbey, London, pp 25-26
8. Pollera CF, Giannarelli D (1989) Prognostic factors influencing cisplatin-induced emesis. Definition and validation of a predictive logistic model. Cancer 64:1117-1122 (Pubitemid 19208867)
9. Tonato M, Roila F, Del Favero A (1991) Methodology of antiemetic trials: a review. Ann Oncol 2:107-114
10. Booth CM, Clemons M, Dranitsaris G, Joy A, Young S, Callaghan W, Trudeau M, Petrella T (2007) Chemotherapy-induced nausea and vomiting in breast cancer patients: a prospective observational study. J Support Oncol 5:374-380 (Pubitemid 47559694)
11. Osoba D, Zee B, Pater J, Warr D, Latreille J, Kaizer L (1997) Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 15:116-123
12. Schwartzberg LS (2007) Chemotherapy-induced nausea and vomiting: clinician and patient perspectives. J Support Oncol 5:5-12 (Pubitemid 46344212)
13. Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, Daniele B, De Pouvourville G, Rubenstein EB, Daugaard G (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Perception versus reality. Cancer 100:2261-2268 (Pubitemid 38580348)
14. Gralla RJ, Osoba D, Kris MG et al (1999) Recommendations for use of antiemetics: evidence-based clinical practice guidelines. J Clin Oncol 17:2971-2994 (Pubitemid 29415258)
15. Kris MG, Hesketh PJ, Somerfield MR et al (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24:2932-2947 (Pubitemid 46630595)
16. Lindley CM, Hirsch JD, O'Neill CV et al (1992) Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1:331-340
17. Martin AR, Pearson JD, Cai B et al (2003) Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall. Support Care Canc 11:522-527 (Pubitemid 36994435)
18. Ballatori E, Roila F (2003) Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy. Health Qual Life Outcomes 1:46
19. Hesketh PJ (1999) Defining the emotogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist 4:191-196 (Pubitemid 29297482)
20. McNemar's test for correlated proportions. Available from URL: http://faculty.vassar.edu/lowry/VassarStats.html. Accessed 28 December 2009
21. Molassiotis A, Saunders MP, Valle J, Wilson G, Lorigan P, Wardley A, Levine E, Cowan R, Loncaster J, Rittenberg C (2008) A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre. Support Care Canc 16:201-208
22. Hesketh PJ, Aapro M, Street J, Carides A (2009) Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer 18:1171-1177
23. Ellebaek E, Herrstedt J (2008) Optimizing antiemetic therapy in multiple-day and multiple cycles of chemotherapy. Curr Opin Support Palliat Care 2:28-34